Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs Manhattan Associates Inc (MANH) Price & Performance

Enveric Biosciences IncTrade
Manhattan Associates IncTrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs Manhattan Associates Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Manhattan Associates Inc trades at $190.49 (market cap $11.38B). The key difference: Manhattan Associates Inc is far larger — about 1835.5× Enveric Biosciences Inc's market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.

ENVBMANH
Market Cap
$6.20M$11.38B
Sector
HealthTechnology
52-Week High
$17.40$220.19
52-Week Low
$1.27$120.88
Enterprise Value
$1.30M$11.25B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.

Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.

Manhattan Associates Inc

MANH trades at $195.23, up 2.41% in the last 24 hours, with a bullish technical outlook supported by a golden cross and strong momentum indicators. The company reported Q2 2026 EPS of $1.39, beating estimates, and maintains robust profitability with an 18.67% net income margin. However, high valuation ratios like a P/E of 56.07 and ongoing legal investigations pose concerns.

Outlook is positive with an 80% analyst buy rating and a $210.33 consensus price target, implying ~8% upside. Key risks include elevated valuation multiples and fiduciary duty investigations by Rosen Law Firm, which could impact investor confidence near-term.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About Manhattan Associates Inc

Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.

Read more on MANH